Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VK2809 · 2 trials · 3 indications
Relative change in liver fat content (assessed by MRI-PDFF) from baseline to Week 12 in subjects treated with VK2809 compared to the change in subjects treated with placebo.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| 1.0 mg | EXPERIMENTAL | - |
| 2.5mg | EXPERIMENTAL | - |
| 5.0 mg | EXPERIMENTAL | - |
| 10 mg | EXPERIMENTAL | - |
| VK2809 (5mg) | EXPERIMENTAL | 5mg VK2809 capsule |
| VK2809 (10mg) | EXPERIMENTAL | 10mg VK2809 capsule |
| VK2809 (10mg QOD) | EXPERIMENTAL | 10mg VK2809 capsule |
| Name | Type | Description |
|---|---|---|
| VK2809 | DRUG | Capsule |
| Placebos | DRUG | Capsule |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Provide a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study and is willing and able to participate; 2. Have a histologically-confirmed diagnosis of...
VK2809 is an investigational small molecule being developed for hyperlipidemia and nonalcoholic steatohepatitis (NASH). It has been studied in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease, as well as in subjects with biopsy-proven NASH. The drug is currently in Phase 2 clinical development.
VK2809 is a thyroid hormone receptor beta agonist. It works by selectively activating the thyroid hormone receptor beta, which plays a role in lipid metabolism and liver function. This mechanism is being investigated for its potential effects on cholesterol levels and liver fat in conditions like hyperlipidemia and NASH.
VK2809 is being developed by Viking Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VKTX. The company is conducting clinical trials to evaluate the safety and efficacy of VK2809 in patients with hyperlipidemia and nonalcoholic steatohepatitis.
VK2809 is in Phase 2 clinical development. It has completed two Phase 2 trials, including a study in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease, and a larger study in subjects with biopsy-proven NASH. The drug is not yet approved and remains investigational.
VK2809 has completed two Phase 2 clinical trials. The first, NCT02927184, evaluated safety and tolerability in 59 patients with primary hypercholesterolemia and non-alcoholic fatty liver disease in the United States. The second, NCT04173065, assessed efficacy and safety over 52 weeks in 248 subjects with biopsy-proven NASH across multiple countries.
VK2809 is the primary name used for this investigational compound in clinical trials and scientific literature. No alternative names have been reported for this drug in the available clinical trial information. It is a distinct small molecule being developed by Viking Therapeutics for metabolic and liver conditions.